Safety ·
This article explores the implications of discontinuation and weight regain associated with next-generation GLP-1 receptor drugs, particularly in the context of findings from the STEP and SURMOUNT trials and the anticipated developments in quad-agonist therapies.
The big picture
The landscape of obesity and metabolic disorder treatments is rapidly evolving, particularly with the advent of multi-agonist therapies. Retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, and glucagon, is currently in Phase 3 trials, but its approval status remains pending. As the field anticipates the potential impact of quad-agonists, it is essential to consider what the current trials, such as STEP and SURMOUNT, reveal about patient experiences during discontinuation and the subsequent risk of weight regain.
How it works
Multi-agonist therapies, like Retatrutide, aim to engage multiple pathways involved in metabolism and weight regulation. By activating GLP-1, GIP, and glucagon receptors, these agents are hypothesized to enhance satiety, improve insulin sensitivity, and promote energy expenditure. The rationale for developing quad-agonists is to further amplify these effects, potentially yielding greater weight loss and metabolic improvements. However, the complexity of receptor interactions necessitates thorough investigation to understand their full implications.
Key points at a glance
- Retatrutide is a triple agonist in Phase 3 trials targeting GLP-1, GIP, and glucagon.
- Tirzepatide is an approved dual agonist of GLP-1 and GIP.
- Current trials, such as STEP and SURMOUNT, have highlighted the challenges of weight regain upon discontinuation of GLP-1 therapies.
- Quad-agonist therapies are still in early clinical or preclinical stages, with no approvals to date.
- Potential candidates for quad-agonism include compounds from various pharmaceutical companies, but their efficacy and safety profiles remain under investigation.
- Understanding the mechanisms of weight regain can inform future treatment strategies and patient management.
Where this fits in the pipeline
As of now, no quad-agonist or penta-agonist therapies are approved. However, several candidates are in various stages of development. For example, HM15275 from Hanmi and CT-388 from Roche/Carmot are among those exploring quad-agonist formulations. These therapies are expected to build upon the foundational knowledge gained from existing dual agonists like Tirzepatide and the insights gleaned from the current clinical trials. Each company is likely to disclose further data as these programs progress through early phases of clinical evaluation.
What it could mean for patients
For patients, the emergence of quad-agonists could potentially enhance treatment options, offering more comprehensive metabolic control and improved weight management. However, the data from STEP and SURMOUNT indicate that discontinuation of existing therapies can lead to significant weight regain, raising concerns about the sustainability of treatment effects. Future therapies will need to address these challenges to optimize long-term patient outcomes.
Open questions and what we don't yet know
Despite the promising potential of quad-agonists, several questions remain unanswered. The exact mechanisms underlying weight regain after discontinuation of therapies like Retatrutide are not fully understood. Furthermore, the safety profiles of multi-agonists, particularly concerning long-term use, are still being evaluated. Regulatory hurdles, including the need for robust clinical data demonstrating efficacy and safety, will also influence the timeline for these therapies reaching the market.
Bottom line
Next-generation GLP-1 therapies, particularly quad-agonists, hold promise for advancing obesity treatment, but understanding the implications of discontinuation and weight regain is critical for patient management. Ongoing trials will continue to shape the future landscape of metabolic therapies.
This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.